Genetic abnormalities defining AML primarily include t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 (12 %), the NPM1 mutation (25–30 %), isocitrate dehydrogenase (IDH) mutations (15–20 %), the FLT3-ITD mutation (40 %), t(9;11)(p21.3;q23.3)/MLLT3::KMT2A, inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11, t(6;9)(p23;q24)/ DEK::NUP214, and inv(3)(q21.3q26.2).1 This evidence concerns the gene MLLT3 and acute myeloid leukemia.